Astellas files for degarelix approval in Japan
This article was originally published in Scrip
Executive Summary
Astellas has filed an application in Japan for the approval of the gonadotropin-releasing hormone receptor antagonist, degarelix acetate (ASP3550), for the treatment of prostate cancer.